Last reviewed · How we verify

Ara-C±IDA — Competitive Intelligence Brief

Ara-C±IDA (Ara-C±IDA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (nucleoside analog + anthracycline). Area: Oncology.

phase 3 Combination chemotherapy (nucleoside analog + anthracycline) DNA polymerase (Ara-C); Topoisomerase II (IDA) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ara-C±IDA (Ara-C±IDA) — Sunshine Lake Pharma Co., Ltd.. Ara-C±IDA is a combination chemotherapy regimen that inhibits DNA synthesis and induces apoptosis in rapidly dividing cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ara-C±IDA TARGET Ara-C±IDA Sunshine Lake Pharma Co., Ltd. phase 3 Combination chemotherapy (nucleoside analog + anthracycline) DNA polymerase (Ara-C); Topoisomerase II (IDA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (nucleoside analog + anthracycline) class)

  1. Sunshine Lake Pharma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ara-C±IDA — Competitive Intelligence Brief. https://druglandscape.com/ci/ara-c-ida. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: